A phase IV study, prospective, randomised, open label, blinded endpoint, parallel group, 9 weeks of comparison between oral administration of telmisartan tablet (80mg once daily) and amlodipine tablet (10 mg once daily) on biological PPAR gamma [peroxisome proliferator-activated receptor gamma] activities in non controlled hypertensive male patients
Phase of Trial: Phase IV
Latest Information Update: 11 Nov 2008
At a glance
- Drugs Amlodipine; Telmisartan
- Indications Hypertension
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 11 Nov 2008 Last updated from ClinicalTrials.gov record.
- 01 Feb 2008 Status changed from recruiting to completed.